Skip to main content
SpringerLink
Log in
Book cover

Translational Vascular Medicine pp 17–25Cite as

Benefits and Risks of Manipulating the HIF Hydroxylase Pathway in Ischemic Heart Disease

  • Chapter
  • First Online:

Abstract

Ischemic heart disease is a major cause of morbidity and mortality in the Western world. It occurs when oxygen delivery cannot meet the metabolic needs of the heart, as observed in patients with stable coronary artery disease as well as those experiencing acute myocardial infarction. Although conditions leading to myocardial injury have been well studied, and physical means of revascularization by stenting or coronary bypass surgery are well developed, there remains a need to define treatments that limit damage in the acute phase or promote revascularization by medical means. In particular, mechanisms that preserve cellular function during ischemia remain poorly understood.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Kaelin Jr WG, Ratcliffe PJ. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell. 2008;30:393–402.

    Article  PubMed  CAS  Google Scholar 

  2. Cai Z, Manalo DJ, Wei G, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation. 2003;108:79–85.

    Article  PubMed  CAS  Google Scholar 

  3. Cai Z, Zhong H, Bosch-Marce M, et al. Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res. 2008;77:463–70.

    Article  PubMed  CAS  Google Scholar 

  4. Eckle T, Kohler D, Lehmann R, El Kasmi K, Eltzschig HK. Hypoxia-inducible factor-1 is central to cardioprotection: a new paradigm for ischemic preconditioning. Circulation. 2008;118:166–75.

    Article  PubMed  CAS  Google Scholar 

  5. Kido M, Du L, Sullivan CC, et al. Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse. J Am Coll Cardiol. 2005;46:2116–24.

    Article  PubMed  CAS  Google Scholar 

  6. Elson DA, Thurston G, Huang LE, et al. Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha. Genes Dev. 2001;15:2520–32.

    Article  PubMed  CAS  Google Scholar 

  7. Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene delivery to myocardium: deleterious effects of unregulated expression. Circulation. 2000;102:898–901.

    PubMed  CAS  Google Scholar 

  8. Carmeliet P. VEGF gene therapy: stimulating angiogenesis or angioma-genesis? Nat Med. 2000;6:1102–3.

    Article  PubMed  CAS  Google Scholar 

  9. Kant R, Diwan V, Jaggi AS, Singh N, Singh D. Remote renal preconditioning-induced cardioprotection: a key role of hypoxia inducible factor-prolyl 4-hydroxylases. Mol Cell Biochem. 2008;312:25–31.

    Article  PubMed  CAS  Google Scholar 

  10. Dendorfer A, Heidbreder M, Hellwig-Burgel T, Johren O, Qadri F, Dominiak P. Deferoxamine induces prolonged cardiac preconditioning via accumulation of oxygen radicals. Free Radic Biol Med. 2005;38:117–24.

    Article  PubMed  CAS  Google Scholar 

  11. Xi L, Taher M, Yin C, Salloum F, Kukreja RC. Cobalt chloride induces delayed cardiac preconditioning in mice through selective activation of HIF-1alpha and AP-1 and iNOS signaling. Am J Physiol Heart Circ Physiol. 2004;287:H2369–75.

    Article  PubMed  CAS  Google Scholar 

  12. Zhao HX, Wang XL, Wang YH, et al. Attenuation of myocardial injury by postconditioning: role of hypoxia inducible factor-1alpha. Basic Res Cardiol. 2010;105:109–18.

    Article  PubMed  CAS  Google Scholar 

  13. Ockaili R, Natarajan R, Salloum F, et al. HIF-1 activation attenuates postischemic myocardial injury: role for heme oxygenase-1 in modulating microvascular chemokine generation. Am J Physiol Heart Circ Physiol. 2005;289:H542–8.

    Article  PubMed  CAS  Google Scholar 

  14. Philipp S, Jurgensen JS, Fielitz J, et al. Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats. Eur J Heart Fail. 2006;8:347–54.

    Article  PubMed  CAS  Google Scholar 

  15. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J. 2003;22:4082–90.

    Article  PubMed  CAS  Google Scholar 

  16. Natarajan R, Salloum FN, Fisher BJ, Kukreja RC, Fowler 3rd AA. Hypoxia inducible factor-1 activation by prolyl 4-hydroxylase-2 gene silencing attenuates myocardial ischemia reperfusion injury. Circ Res. 2006;98:133–40.

    Article  PubMed  CAS  Google Scholar 

  17. Natarajan R, Salloum FN, Fisher BJ, Ownby ED, Kukreja RC, Fowler 3rd AA. Activation of hypoxia-inducible factor-1 via prolyl-4 hydoxylase-2 gene silencing attenuates acute inflammatory responses in postischemic myocardium. Am J Physiol Heart Circ Physiol. 2007;293:H1571–80.

    Article  PubMed  CAS  Google Scholar 

  18. Huang M, Chan DA, Jia F, et al. Short hairpin RNA interference therapy for ischemic heart disease. Circulation. 2008;118:S226–33.

    Article  PubMed  CAS  Google Scholar 

  19. Takeda K, Ho VC, Takeda H, Duan LJ, Nagy A, Fong GH. Placental but not heart defects are associated with elevated hypoxia-inducible factor alpha levels in mice lacking prolyl hydroxylase domain protein 2. Mol Cell Biol. 2006;26:8336–46.

    Article  PubMed  CAS  Google Scholar 

  20. Hyvarinen J, Hassinen IE, Sormunen R, et al. Hearts of hypoxia-inducible factor prolyl 4-hydroxylase-2 hypomorphic mice show protection against acute ischemia-reperfusion injury. J Biol Chem. 2010;285:13646–57.

    Article  PubMed  Google Scholar 

  21. Adluri RS, Thirunavukkarasu M, Dunna NR, et al. Disruption of HIF-prolyl hydroxylase-1 (PHD-1-/-) attenuates ex vivo myocardial ischemia/reperfusion injury through HIF-1alpha transcription factor and its target genes in mice. Antiox Redox Signal 2011;15:1789–97.

    Google Scholar 

  22. Aragones J, Schneider M, Van Geyte K, et al. Deficiency or inhibition of oxygen sensor Phd1 induces hypoxia tolerance by reprogramming basal metabolism. Nat Genet. 2008;40:170–80.

    Article  PubMed  CAS  Google Scholar 

  23. Schneider M, Van Geyte K, Fraisl P, et al. Loss or silencing of the PHD1 prolyl hydroxylase protects livers of mice against ischemia/reperfusion injury. Gastroenterology. 2010;138:1143–54. e1–2.

    Article  PubMed  CAS  Google Scholar 

  24. Zhang Q, Gu J, Li L, et al. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009;16:413–24.

    Article  PubMed  CAS  Google Scholar 

  25. Moslehi J, Minamishima YA, Shi J, et al. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. Circulation. 2010;122:1004–16.

    Article  PubMed  CAS  Google Scholar 

  26. Bekeredjian R, Walton CB, MacCannell KA, et al. Conditional HIF-1alpha expression produces a reversible cardiomyopathy. PLoS One. 2010;5:e11693.

    Article  PubMed  Google Scholar 

  27. Morin Y, Daniel P. Quebec beer-drinkers’ cardiomyopathy: etiological considerations. Can Med Assoc J. 1967;97:926–8.

    PubMed  CAS  Google Scholar 

  28. Minamishima YA, Moslehi J, Bardeesy N, Cullen D, Bronson RT, Kaelin Jr WG. Somatic inactivation of the PHD2 prolyl hydroxylase causes polycythemia and congestive heart failure. Blood. 2008;111:3236–44.

    Article  PubMed  CAS  Google Scholar 

  29. Minamishima YA, Moslehi J, Padera RF, Bronson RT, Liao R, Kaelin Jr WG. A feedback loop involving the Phd3 prolyl hydroxylase tunes the mammalian hypoxic response in vivo. Mol Cell Biol. 2009;29:5729–41.

    Article  PubMed  CAS  Google Scholar 

  30. Takeda K, Aguila HL, Parikh NS, et al. Regulation of adult erythropoiesis by prolyl hydroxylase domain proteins. Blood. 2008;111:3229–35.

    Article  PubMed  CAS  Google Scholar 

  31. Takeda K, Cowan A, Fong GH. Essential role for prolyl hydroxylase domain protein 2 in oxygen homeostasis of the adult vascular system. Circulation. 2007;116:774–81.

    Article  PubMed  CAS  Google Scholar 

  32. Bishop T, Gallagher D, Pascual A, et al. Abnormal sympathoadrenal development and systemic hypotension in PHD3-/- mice. Mol Cell Biol. 2008;28:3386–400.

    Article  PubMed  CAS  Google Scholar 

  33. Gale DP, Harten SK, Reid CD, Tuddenham EG, Maxwell PH. Autosomal dominant erythrocytosis and pulmonary arterial hypertension associated with an activating HIF2 alpha mutation. Blood. 2008;112:919–21.

    Article  PubMed  CAS  Google Scholar 

  34. Gnarra JR, Ward JM, Porter FD, et al. Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci USA. 1997;94:9102–7.

    Article  PubMed  CAS  Google Scholar 

  35. Lei L, Mason S, Liu D, et al. Hypoxia-inducible factor-dependent degeneration, failure, and malignant transformation of the heart in the absence of the von Hippel-Lindau protein. Mol Cell Biol. 2008;28:3790–803.

    Article  PubMed  CAS  Google Scholar 

  36. Willam C, Maxwell PH, Nichols L, et al. HIF prolyl hydroxylases in the rat; organ distribution and changes in expression following hypoxia and coronary artery ligation. J Mol Cell Cardiol. 2006;41:68–77.

    Article  PubMed  CAS  Google Scholar 

  37. Zhao ZQ, Corvera JS, Halkos ME, et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol. 2003;285:H579–88.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK

    Tammie Bishop & Peter J. Ratcliffe

Authors
  1. Tammie Bishop
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Peter J. Ratcliffe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tammie Bishop .

Editor information

Editors and Affiliations

  1. University College London, Gower Street, London, WC1E 6BT, United Kingdom

    David Abraham

  2. The Royal Free & Univ College Med School, Gower Street, London, WC1E 6BT, United Kingdom

    Clive Handler

  3. University College London, Gower Street, London, WC1E 6BT, United Kingdom

    Michael Dashwood

  4. The Royal Free & Univ College Med School, Gower Street, London, WC1E 6BT, United Kingdom

    Gerry Coghlan

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag London Limited

About this chapter

Cite this chapter

Bishop, T., Ratcliffe, P.J. (2012). Benefits and Risks of Manipulating the HIF Hydroxylase Pathway in Ischemic Heart Disease. In: Abraham, D., Handler, C., Dashwood, M., Coghlan, G. (eds) Translational Vascular Medicine. Springer, London. https://doi.org/10.1007/978-0-85729-920-8_2

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-920-8_2

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-919-2

  • Online ISBN: 978-0-85729-920-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation